http://rdf.ncbi.nlm.nih.gov/pubchem/reference/34618813

Outgoing Links

Predicate Object
contentType Journal Article
issn 2234-943X
pageRange 746526-
publicationName Frontiers in Oncology
startingPage 746526
bibliographicCitation Chen T, Xie R, Zhao Q, Cai H, Yang L. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China. Front Oncol. 2022;12():746526. PMID: 35936702; PMCID: PMC9353739.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_497f3cfb75e712da2f46a662f309b70c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_da71effcf27a095df4849861a46c994e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c701cf0a1dabd2de619e7522420ee6a9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3258c30f173757674f33abd6e549a741
date 2022-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/PMC9353739
https://doi.org/10.3389/fonc.2022.746526
https://pubmed.ncbi.nlm.nih.gov/35936702
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39509
https://portal.issn.org/resource/ISSN/2234-943X
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID108157
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Total number of triples: 24.